In addition, many studies have suggested that estrogen positive premenopausal breast cancer has distinct molecular characteristics compared to postmenopausal cancers and behaves differently with distinct integrin/laminin and EGFR signalling pathways [34–36]. This evidence concerns the gene EGFR and cancer.